<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05104138</url>
  </required_header>
  <id_info>
    <org_study_id>1010/2021</org_study_id>
    <nct_id>NCT05104138</nct_id>
  </id_info>
  <brief_title>Eplerenone Versus PDT: Comparative Study by OCTA</brief_title>
  <official_title>OCTA in Central Serous Chorioratinopathy Treated With Oral Eplerenone or Hal-fluence Photodynamic Therapy: a Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to analyze the changes in OCTA parameters and in choroidal thickness in&#xD;
      patients affected by central serous chorioretinopathy treated by oral eplerenone and&#xD;
      half-fluence photodynamic therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central serous chorioretinopathy (CSC) is a chorioretinal disease characterized by serous&#xD;
      detachment due to the dilatation and hyperpermeability of choroidal vessels resulting in the&#xD;
      accumulation of serous fluid between the neurosensory retina and the retinal pigment&#xD;
      epithelium.&#xD;
&#xD;
      Several studies reported the efficacy of half-fluence photodynamic therapy (PDT) and oral&#xD;
      eplerenone in the CSC treatment inducing a reduction of the choroidal hyperpermeability and&#xD;
      remodeling the choroidal vascularization.&#xD;
&#xD;
      This retrospective study aims to perform a quantitative analysis of retinal and CC vessel&#xD;
      density by OCTA at baseline, 3 and 6 months in patients underwent PDT and patients underwent&#xD;
      eplerenone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study of vessel density in retinal choriocapillaris networks, using OCTA, in patients underwent half fluence photodynamic therapy and oral eplerenone</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the role of optical coherence tomography angiography in predicting the changes of the vessel density of retinal and choriocapillaris vascular networks , comparing patients underwent half-fluence phodynamic therapy and patients with oral eplerenone.&#xD;
The vessel density are expressed as percentage</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>Half fluence photodynamic therapy</arm_group_label>
    <description>Patients with central serous chorioretinopathy, treated by half-fluence photodynamic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Eplerenone</arm_group_label>
    <description>Patients with central serous chorioretinopathy, treated by oral eplerenone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>The patients underwent eplerenone treatment for 6 months</description>
    <arm_group_label>Oral Eplerenone</arm_group_label>
    <other_name>Eplerenone in oral dose form</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The patients underwent half fluence photodynamic therapy for 6 months</intervention_name>
    <description>Half fluence photodynamic therapy for 6 months</description>
    <arm_group_label>Half fluence photodynamic therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The participans were older than 40 years with central serous chorioretinopathy. They did&#xD;
        not present other ophthalmological diseases&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age older than 30 years&#xD;
&#xD;
          -  diagnosis of central serous chorioretinopathy&#xD;
&#xD;
          -  treatment-naïve with half-fluence photodynamic therapy or oral eplerenone&#xD;
&#xD;
          -  absence of vitreoretinal and vascular retinal diseases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age younger than 30 years&#xD;
&#xD;
          -  absence of diagnosis of central serous chorioretinopathy&#xD;
&#xD;
          -  previous treatment with half-fluence photodynamic therapy or oral eplerenone&#xD;
&#xD;
          -  presence of concomitant vitreoretinal and vascular retinal diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Gilda Cennamo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università Federico II</affiliation>
  </overall_official>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Gilda Cennamo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

